Ocular Therapeutix™ Reports Positive Topline Clinical Data for the First of Two Phase 3 Clinical Trials Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and Pain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ocular Therapeutix (OCUL) Target Raised to $49 at Oppenheimer; Positive Data Validates Platform
March 11, 2015 7:38 AM EDTOppenheimer analyst Yigal Nochomovitz reiterated an Outperform-rated and boosted his price target on Ocular Therapeutix (NASDAQ: OCUL) to $49.00 (from $42.00) saying positive Phase 3a data validates its technology platform.
commenetd, "Ocular reported positive OTX-DP Phase 3a top-line data in post-surgical pain/inflammation as expected. Both... More
Ocular Therapeutix (OCUL) Price Target Raised to $50 at RBC
March 10, 2015 3:59 PM EDTRBC Capital maintained an Outperform rating on Ocular Therapeutix (NASDAQ: OCUL) and raised its price target to $50.00 (from $35.00).
Analyst Adnan Butt said, "OCULs platform technology is already paying off with: (1) One positive Phase III reading out, (2) 5 clinical programs (2 Phase IIIs and 2 Phase IIs), (3) Pipeline surprises... More
Ocular Therapeutix (OCUL) Tops Q4 EPS by 1c
March 10, 2015 6:46 AM EDTOcular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.37), $0.01 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $505 thousand versus the consensus estimate of $200 thousand.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
... MoreOcular Therapeutix (OCUL) Announces OTX-DP Met Primary Endpoints in First Phase 3
March 10, 2015 6:33 AM EDTOcular Therapeutix (NASDAQ: OCUL) announced positive topline data from the first of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP (Sustained Release Dexamethasone), for the treatment of ocular inflammation and pain following cataract surgery. The Phase 3a study, which enrolled 247 patients, met both primary efficacy measures, achieving a statistically significant improvement in the reduction of inflammatory cells and pain. 33.7% of OTX-DP-treated patients showed an absence of inflammatory cells in the anterior chamber of the study eye on day 14 following drug product insertion, compared to 14.6% of those receiving placebo... More
